Creating lung cancer organoids from patient tissue and blood samples
Lung Cancer Organoids and Patient Derived Tumor Xenografts
Maastricht Radiation Oncology · NCT05092009
This study is trying to create mini lung cancer models from tissue and blood samples of patients to better understand the disease and find personalized treatments.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 600 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Maastricht Radiation Oncology (other) |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 3 sites (Heerlen and 2 other locations) |
| Trial ID | NCT05092009 on ClinicalTrials.gov |
What this trial studies
This observational study aims to collect extra tissue and blood samples from patients undergoing standard procedures for lung cancer diagnosis and treatment. The collected materials will be used to generate matched normal and lung cancer organoids, which can help in understanding the disease better and developing personalized treatment approaches. Patients will not undergo any additional procedures beyond what is required for their standard care. The study focuses on utilizing biopsies and surgical resection materials to create these organoids.
Who should consider this trial
Good fit: Ideal candidates include patients with suspected lung cancer who are scheduled for bronchoscopy or surgical resection.
Not a fit: Patients who do not have lung cancer or are not undergoing the specified procedures may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more personalized and effective treatments for lung cancer patients.
How similar studies have performed: Other studies have shown promise in using organoids for cancer research, indicating that this approach could be beneficial.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * All patients selected to undergo primary surgical resection of a primary lung cancer. All types of resection are eligible, e.g. wedge resection, segmental resection, lobectomy, pneumonectomy. * All patients with (suspected) lung cancer that will undergo a bronchoscopy or endobronchial ultrasound guided transbronchial needle aspiration (EBUS/EUS-TBNA) bronchoscopy. Exclusion Criteria: There are no exclusion criteria
Where this trial is running
Heerlen and 2 other locations
- Zuyderland Medical Center — Heerlen, Netherlands (RECRUITING)
- Maastricht Radiation Oncology (Maastro) — Maastricht, Netherlands (NOT_YET_RECRUITING)
- MUMC+ — Maastricht, Netherlands (RECRUITING)
Study contacts
- Study coordinator: Chantal Overhof, BEc.
- Email: chantal.overhof@maastro.nl
- Phone: +31 88 44 55 863
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Lung Cancer